Table 3.
Characteristics and biopsy outcomes of patients with prior negative SB at vs outside NCI
| Mean Before Matching |
Mean After Matching |
|||||||
|---|---|---|---|---|---|---|---|---|
| NCI | Outside | Difference | p Value | NCI | Outside | Difference | p Value | |
| No. pts | 425 | 186 | 263 | 186 | ||||
| Age | 62.6 | 65.6 | 3 | <0.0001 | 65 | 65.6 | 0.6 | 0.4041 |
| PSA (ng/ml) | 14.1 | 12.4 | −1.7 | 0.7764 | 11.6 | 12.4 | 0.8 | 0.7566 |
| % Suspicion: | 0.0002 | 0.6966 | ||||||
| Low | 11.3 | 6.5 | −4.8 | 7 | 6.5 | −0.5 | ||
| Moderate | 71.8 | 87.1 | 15.3 | 88.5 | 87.1 | −1.4 | ||
| High | 16.9 | 6.5 | −10.5 | 4.5 | 6.5 | 2 | ||
| % CDR: | ||||||||
| By FB | 32.5 | 48.9 | 16.5 | 0.0002 | 31.8 | 48.9 | 17.1 | 0.0029 |
| By SB + FB | 39.8 | 61.3 | 21.5 | <0.0001 | 40.1 | 61.3 | 21.2 | 0.0002 |
| % Upgrading: | ||||||||
| By FB | 46.2 | 42.1 | −4 | 0.5822 | 44.7 | 42.1 | −2.6 | 0.7774 |
| By SB | 21.9 | 28.9 | 7.1 | 0.2269 | 28.1 | 28.9 | 0.9 | 0.9204 |
| Clinically significant* by FB | 30.2 | 27.2 | −3 | 0.6824 | 29.7 | 27.2 | −2.5 | 0.7706 |
| Clinically significant* by SB | 6.5 | 6.1 | −0.4 | 1 | 14 | 6.1 | −7.9 | 0.1552 |
*
Defined as Gleason 3 + 4 = 7 or greater.